GSK plc announced on May 28, 2025, that the Phase 3 PIVOT-PO trial for tebipenem HBr was stopped early for efficacy after reviewing data from 1,690 patients, potentially offering the first oral treatment for complicated urinary tract infections in the U.S. This development is significant as it addresses a substantial healthcare issue with approximately 2.9 million cases treated annually in the U.S., contributing to over $6 billion in healthcare costs.